| Literature DB >> 23874159 |
Jill Luoto1, Margaret A Maglione, Breanne Johnsen, Christine Chang, Elizabeth S Higgs, Tanja Perry, Paul G Shekelle.
Abstract
Entities:
Mesh:
Year: 2013 PMID: 23874159 PMCID: PMC3706307 DOI: 10.1371/journal.pmed.1001469
Source DB: PubMed Journal: PLoS Med ISSN: 1549-1277 Impact factor: 11.069
Summary of existing public health frameworks considered.
| Framework name | Grades Assigned/What the Framework Rates | Domains for Grading Evidence | Notes on Domains |
|
| Grades of 1, strong; 2, weak; 3, insufficient. Expanded categories include 2A, probable; 2B, possible; and 2C, limited. | Association | “High” association is defined as a RR of greater than 2. Otherwise “low” or “none.” |
| Repeatability | Wide or limited | ||
| How it works | How it works is known or not known | ||
|
| Four grades assigned: high, moderate, low, and very low quality of evidence. | Randomized trials start with a “high” initial quality grade, observational studies start with a “low” grade. | Grades can be moved down depending on factors such as risk of bias or inconsistency, or up in light of a large measured effect or evidence of a dose-response. |
|
| Four grades assigned: 1, strong; 2, conditional; 3, insufficient; 4, inappropriate. Grade 2, conditional, has subcategories of probable, possible, and pending. | Efficacy | Whether consistent, limited or inconsistent |
| Biological plausibility | |||
| Implementation data availability | Whether available or not | ||
|
| Evidence is characterized as strong, sufficient, or insufficient. | Execution | Good or fair |
| Design suitability | Greatest (RCTs), moderate (no concurrent comparison group), or least | ||
| Number of studies | |||
| Consistent | “Generally consistent in direction and size” | ||
| Effect size | Sufficient or large, defined on a case-by-case basis based on Task Force opinion | ||
| Expert opinion | Whether used or not | ||
|
| Four grades assigned: A, excellent; B, good; C, satisfactory; D, poor. Grade A can be trusted to guide practice; grade D concludes the body of evidence is weak and recommendation must be applied with caution. | Evidence base | “Evidence hierarchy” places systematic reviews of RCTs with “low risk of bias” highest |
| Consistency of evidence | |||
| Clinical impact | Very large, substantial, moderate, slight | ||
| Generalizability | Highest grade awarded if “population/s studied in body of evidence are | ||
| Applicability | |||
|
| Four grades assigned: A, B, C, and D. | Efficacy | High quality meta-analyses and systematic reviews of RCTs with very low risk of bias rated highest level of evidence. |
| Evidence of corroboration | Strong evidence of corroboration defined as “Consistent findings in two or more studies of ++ quality carried out within the UK and applicable to the target population, providing evidence on salience and implementation.” ++ is defined as is efficacy above. |
Results on three exemplars applied to six evidence frameworks.
| Exemplar | Outcomes | Tang et al. | GRADE | HASTE | USCPSTF | NHMRC | NHS Health Development Agency |
|
| Diarrhea | Grade 2b level 1 possible | ⊕⊕⊕ Moderate quality of evidence | Grade 2b - Possible | Strong | “C” - Satisfactory | “B” |
|
| HIV infection in child within year of birth | Grade 2b level 1 possible | ⊕⊕⊕⊕ High quality of evidence | Grade 1- Strong | Strong | “A” - Excellent | “A” |
|
| Morbidity in children under 5 | Grade 2b level 2 possible | ⊕⊕ Low quality of evidence | Grade 3 - Insufficient | Strong | “B” - Good | “C” |
Tang et al. grade for PMTCT is due to strict rule that only interventions with relative risk (RR)>2 qualify as “strong” evidence. If this rule is flexible we would rate PMTCT as “Grade 1 Level 1 Strong” by Tang et al. categorizations.
Grade 2c level 2 if repeatability outside Southeast Asia is not considered acceptable.